U.S. Markets open in 22 mins
  • Crude Oil

    70.51
    -0.05 (-0.07%)
     
  • Gold

    1,768.40
    -9.80 (-0.55%)
     
  • Silver

    23.03
    +0.46 (+2.05%)
     
  • EUR/USD

    1.1696
    -0.0034 (-0.2924%)
     
  • 10-Yr Bond

    1.3360
    +0.0120 (+0.91%)
     
  • Vix

    20.87
    -3.49 (-14.33%)
     
  • GBP/USD

    1.3619
    -0.0045 (-0.3282%)
     
  • USD/JPY

    109.7800
    +0.5600 (+0.5127%)
     
  • BTC-USD

    43,486.09
    +1,112.74 (+2.63%)
     
  • CMC Crypto 200

    1,089.55
    +49.07 (+4.72%)
     
  • FTSE 100

    7,083.37
    +102.39 (+1.47%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

3 Reasons Why Pfizer's and Moderna's Vaccine Revenue Growth Is Just Getting Started

·4 min read
3 Reasons Why Pfizer's and Moderna's Vaccine Revenue Growth Is Just Getting Started
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Pfizer (NYSE: PFE) is expecting its coronavirus vaccine to generate a whopping $33.5 billion in revenue this year. Rival Moderna (NASDAQ: MRNA) is likely to offer an update on its vaccine during its quarterly earnings report on Thursday. During the last report, Moderna said advance purchase agreements for the year represented more than $19 billion in product sales.